|
|
CGEN-25009
Compugen has identified a novel peptide that displays strong anti-fibrotic activity. This peptide, designated CGEN-25009, was discovered using Compugen’s GPCR Peptide Ligand Discovery Platform (Shemesh et al. 2008). Initial evaluation in cell-based assays indicated that CGEN-25009 activates LGR7 (RXFP1), the known receptor of H2-relaxin, a multi-functional peptide hormone with known potent anti-fibrotic activity. The relaxin-like activity of CGEN-25009 was also demonstrated using human dermal fibroblasts, showing reduction of TGF-β1-stimulated collagen deposition and increased MMP-2 secretion. The anti-fibrotic and anti-inflammatory effects of CGEN-25009 were demonstrated in-vivo in a mouse model of bleomycin-induced pulmonary fibrosis, in which preventive and therapeutic modes of treatment by CGEN-25009 were found beneficial in reducing the density of the fibrotic tissue and various markers of inflammatory injury, induced by bleomycin. |
|